Drug Discov. 7 426–437; 2008). Increased levels of glutamate have been found in the frontal cortex of patients with MDD, and the non-selective NMDA receptor antagonist ketamine has shown ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

It is the first and only oral NMDA receptor antagonist to be approved for this ... tricyclic or selective serotonin reuptake inhibitor drugs can take weeks to elevate mood, placing severely ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment ...

NMDA receptors are present throughout the brain and are essential for maintaining consciousness. For this reason, she ...

investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor, in Alzheimer’s disease agitation, and results of the ACCORD-2, ADVANCE-2, and long-term safety trials ...